American Fertility Medical Center - Genetic Infertility & Andrology Laboratory, Inc. – FDA 483, Jun 9, 2022
An FDA inspection of American Fertility Medical Center - Genetic Infertility & Andrology Laboratory, Inc. in Irvine, CA, revealed a significant issue regarding the labeling of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). The firm failed to prominently label HCT/Ps from ineligible donors with a Biohazard legend and a warning statement about reactive test results, specifically for embryos derived from an HBc positive donor. This indicates a serious lapse in donor eligibility and product labeling procedures.
- Inspection date
- June 9, 2022
- Product type
- biologics
ID · 48169198-c812-4df2-9cea-905473b95674
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.